A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJamunarani Veeraraghavan, Rachel Schiff, T. Wang et al.|Annals of Oncology|2019Cited by 42
Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patientsAlejandro Contreras, MF Rimawi, Sabrina Herrera et al.|Cancer Research|2013Cited by 18
Does incidence of rash predict treatment response to lapatanib in breast cancer?Jasmine Parma, Meghana V. Trivedi, AC Pavlick et al.|Journal of Clinical Oncology|2011Cited by 1